Galapagos - Pioneering for patients

Welcome

We are Galapagos

We are scientists, entrepreneurs, and pioneers united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life for people around the world.

Discover how we are #LivingInnovation

Pioneering for patients

We are a biotechnology company with operations in Europe and the U.S. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology.

Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most.

To the pipeline Our Approach to Innovation

Our Technology Platforms

Small Molecules

Excellence, speed, agility: fully-integrated, end-to-end in-house capabilities
Best-in-class strategy: validated targets to develop differentiated medicines
25 years of experience: enhanced by external partnerships

Learn more about our innovative approach

Our Technology Platforms

Cell Therapy

Scalable, decentralized, fast: stem-like, early memory cells near patients in median 7 days vein-to-vein
High-yielding discovery engine: multi-targeting, next-generation cell therapies
Diversify and grow: through partnerships and M&A

Discover more

LATEST PRESS RELEASES

07 Dec 2024

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile…

05 Nov 2024

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses….

30 Oct 2024

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy. We are committed to addressing the high unmet needs…

Patient-Focused, Actionable and No Fluff:Insights from the Patient Engagement Council

A cornerstone of our patient-centered commitment is our Patient Engagement Council (PEC), a consultative body that ensures the patient’s perspective helps to shape our strategies and decisions. Learn more about it!

Read

“In giving back, you often gain as much as you give, or even more”Highlights from Galapagos’ Global We Care Day

Each year, we look forward to Global We Care Day – a meaningful opportunity to pause, reflect, and dedicate time to impactful volunteer work. From connecting with the elderly to supporting nature preservation, our teams unite across borders to make a difference where it matters most.

Read

“For Brinda, and for all patients” An Interview with Sri Ramaswami

It’s been one month since we welcomed Sri Ramaswami as Global Head, Corporate Affairs and Investor Relations to Galapagos. His personal experiences, including the loss of close relatives to cancer, have further driven him to dedicate his career to helping communicate life-saving breakthroughs. Get to know Sri in this interview.

Read

Pioneering for Patients, with Patients!

Patients and Carers

At Galapagos, we put patients’ care and well-being first and foremost.

Our goal is to improve patients’ quality of life through life-changing science and innovation.

Discover our commitment to pioneering for patients, with patients!

Discover our commitment